Even with Eli Lilly's endorsement, TRex Bio (TRXB.US) struggles to enjoy a premium, as the issue price drops to the lower limit of $14.
Early-stage biotechnology company TRex Bio has priced its IPO at the lower end of the range at $14 per share, raising $116.7 million and achieving a market capitalization of $384 million. The company will be listed on Nasdaq on Friday, with Eli Lilly expressing interest in increasing its stake.
According to Zhihu Finance APP, early-stage biotechnology company TRex Bio Inc., which focuses on autoimmune and inflammatory diseases, has raised $116.7 million through an IPO, with the offering price set at the lower end of its proposed range.
According to a statement released Thursday, the company sold approximately 8.3 million shares at a price of $14 per share. Previously filed documents indicated that the biotech company had set an offering range of $14 to $16 per share.
Based on the IPO offering price, San Francisco-based TRex has a market value of $384 million, calculated according to the number of outstanding shares listed in the documents.
The company's investors include Eli Lilly, SV Health Investors, Pfizer Ventures, Johnson & Johnson Innovation, Janus Henderson Investors, Alexandria Venture Investments, Delos Capital, and Polaris Partners. Prior filings indicated that Eli Lilly expressed interest in subscribing for shares in this IPO but does not intend to increase its stake to more than 19.9%.
Strong overall volume, diverging returns
TRex is expected to continue the strong momentum for U.S. healthcare IPOs this year. Compiled data shows that biotech and pharmaceutical IPOs have raised nearly $800 million so far this year, almost six times the amount raised during the same period last year.
However, its pricing reflects the direct manifestation of the "overall boom, internal divergence" pattern seen in biopharma IPOs in 2026: the sector's weighted average return this year is about +55%, but almost all the gains come from "platform-based, multi-pipeline, catalyst-nearing" companies.
Looking at subsequent performance, platform-based, multi-pipeline companies (Parabilis, BillionToOne) rose 66% on their debut; single-asset, single-indication companies (Electra) broke issue price on their first day. Investors now price according to "the specific risks of the story" instead of giving a unified premium to the entire sector.
Furthermore, companies that are closer to binary readouts (about to enter Phase 3, or having already filed for listing) are more sought after; companies whose key data won't be available for more than 18 months typically go without a premium or even break below issue price. Companies like TRex Bio, which are "single-asset, Phase 1, with key data expected only by mid-2027," are a segment that the market has started to specifically price down in the second half of the year. Demand for such offerings is real but relatively shallow, and Eli Lilly's strategic endorsement is only enough to bring the deal to market, not to support a price premium within the proposed range.
The company plans to use the funds raised this time to advance its core candidate drug TRB-061, which is currently in early clinical trials for patients with moderate-to-severe atopic dermatitis. Documents show the company expects to release topline data for this investigational therapy by mid-next year. In addition, the company also plans to launch a Phase 1 clinical trial for TRB-071 in the first half of 2027, targeting inflammatory bowel disease.
In January of this year, TRex raised $50 million through a follow-on tranche of Series B preferred shares, with new investors including Janus Henderson and Balyasny Asset Management.
TRex CEO Johnston Erwin worked at Eli Lilly for 36 years before joining the company and previously led Lilly's internal venture arm, Lilly New Ventures.
Previously filed documents show the company had a net loss of $34.8 million in 2025, compared to a net loss of $3.1 million the previous year.
The offering is being led by JPMorgan, Evercore, Cantor Fitzgerald, Stifel Financial, and Wedbush PacGrow. Shares are expected to begin trading Friday on the Nasdaq Global Select Market under the ticker (TRXB.US).
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Updated: SpaceX spectrum trading triggers industry shock, US and European telecom stocks decline
In early trading of the S&P 500 index components, T-Mobile and Verizon led the declines as the European telecom sector fell to its lowest point since January. According to an updated report with stock price data and charts by Rashika Singh from Reuters on October 9, U.S. and European telecom stocks dropped sharply on Friday amid growing concerns about intensified competition in satellite mobile services after SpaceX’s acquisition of low-band spectrum. T-Mobile US, Verizon, and AT&T saw pre-market losses ranging from 5.5% to 7.4%, while the STOXX Europe 600 Telecommunications Index fell over 2% to its lowest level since January 30. Among the largest European telecom operators by market value, Deutsche Telekom dropped 6.5%, Vodafone decreased by 4.1%, Orange fell by 2.3%, and Telefónica dipped 3.9%. The stock declines followed reports (link) that SpaceX agreed to acquire a nationwide 800 MHz spectrum portfolio from private equity firm Grain Management for approximately $8 billion. This move bolsters SpaceX’s ambitions in satellite-to-cellular network connectivity. Analysts at Morgan Stanley commented, “We believe the Grain deal clearly indicates that SpaceX will pursue a more aggressive approach in spectrum acquisitions,” adding that any threat to existing operators would likely emerge gradually, starting with rural markets. Compared to higher-frequency radio waves, low-band spectrum travels longer distances and more effectively penetrates buildings and obstacles, which may facilitate SpaceX in advancing its Starlink Mobile service. Although financial terms were not disclosed by the parties, The Wall Street Journal cited sources valuing the deal at $8 billion. SpaceX shares rose 4% following the announcement, though the transaction is still subject to regulatory approval. [Chart link: https://www.reuters.com/graphics/BRV-BRV/lbvgxnzxepq/chart.png] Communications tower stocks bucked the sector-wide sell-off, as investors bet that SpaceX’s wireless ambitions would ultimately drive demand for more ground infrastructure. American Tower, Crown Castle, and SBA Communications saw gains between 6.7% and 8.3%. Morgan Stanley noted the deal is a “marginal positive” for communications tower operators, pointing out that even satellite-dominated networks may require the deployment of towers, rooftop and small cell sites, and that broader urban competition would necessitate substantial ground-based infrastructure and spectrum resources. (Reuters provides automated translations of its reports in several other languages for the benefit of non-English readers. Automated translations may be inaccurate or lack necessary context, and Reuters does not guarantee the accuracy of translated texts. Automated translations are provided for convenience only, and Reuters is not liable for any damage or loss caused by the use of automated translation services.)
BUZZ - Crescent Energy shares fall as it raises 1.1 billions in equity to acquire Devon
October 9 - Crescent Energy (CRGY.N) shares fell 1% to $12.88 in premarket trading on Friday after the company priced and completed a $1 billion follow-on offering related to an acquisition. The Houston, Texas-based shale oil and gas producer announced late Thursday that it would issue 80 million shares at $12.50 each, representing a 3.9% discount to its most recent closing price. CRGY will use the net proceeds from the offering to help fund its $4.2 billion acquisition of Devon Energy's (DVN.N) Eagle Ford oil and gas assets. A KKR (KKR.N) affiliate, which owns about 7.9% of CRGY, will subscribe to 40 million new shares. JPMorgan, KKR Capital Markets, Raymond James, Evercore, and Wells Fargo Securities will act as joint book-running managers for the offering. CRGY has approximately 330.4 million shares outstanding, with a market capitalization of $4.3 billion. The stock closed down 3.4% on Thursday, narrowing its year-to-date gain to 55%. According to data from London Stock Exchange Group (LSEG), 13 out of 16 analysts rate the stock as "strong buy" or "buy," 2 rate it "hold" and 1 recommends "sell," with a median price target of $18.50. DVN's shares were down 1.4% in premarket trading at $48.22. DVN rose 2.2% on Thursday, bringing its cumulative gain in 2026 to about 34%. (For the convenience of non-English speakers, Reuters has automated the translation of its reports into several other languages. Since automated translation may contain errors or lack necessary context, Reuters does not guarantee the accuracy of automated translation texts and provides them solely for reader convenience. Reuters accepts no liability for any damage or loss caused by the use of automated translation.)
BUZZ - Reports of iPhone production cuts send Apple shares lower
October 9 – According to Nikkei Asia (link), Apple has asked its suppliers to cut production of the new iPhone 18 Pro model due to weak demand, resulting in Apple (AAPL.O) shares falling 1.8% in premarket trading to $334.21. The report states that, against the backdrop of soaring memory chip costs and rising prices, the component orders for October have been reduced by at least 15% compared to initial requirements. Apple has not yet responded to a Reuters request for comment. The current stock price is about 1% lower than the all-time intraday high of $345.34 reached on September 22. According to data compiled by the London Stock Exchange Group (LSEG), the average rating from 43 analysts covering the stock is "Buy," with a median target price of $330. (For the convenience of non-English speakers, Reuters provides automated translations of its report into several other languages. As automated translations may contain errors or lack the required context, Reuters does not guarantee the accuracy of the automated translation and provides it solely for reader convenience. Reuters accepts no liability for any damage or loss resulting from use of the automated translation function.)
Citi maintains a “Neutral” rating on DocuSign (DOCU.O): IAM platform migration shows initial effectiveness, double-digit growth still needs "validation"
Citi published a research report maintaining a "Neutral" rating on the e-signature and agreement cloud platform DocuSign, with a target price of $72.
